Journal
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
Volume 34, Issue 2, Pages 216-226Publisher
SPRINGER INDIA
DOI: 10.1007/s12288-018-0937-x
Keywords
Light chain (AL) amyloidosis; Bortezomib treatment; Effect and safety
Categories
Funding
- National Natural Science Foundation of China [81570106, 814000888, 81600093]
- anticancer major special project of Tianjin [12ZCDZSY18000]
- Tianjin Municipal Natural Science Foundation [14JCYBJC25400, 15JCYBJC24300]
- Tianjin Health and Family Planning Commision [15KG150]
- Tianjin Medical University [YJSCX201717]
Ask authors/readers for more resources
Bortezomib began to be used in the treatment of light chain (AL) amyloidosis in recent years. We performed the first meta-analysis of randomized clinical trials and clinical controlled trials to evaluate the effect and safety of bortezomib treatment for AL amyloidosis. We conducted a search (until July 2016) in electronic databases (PubMed databases and the Cochrane Central Register of Controlled Trials bases from the year 2003). There were 205 records we searched and eight studies was included (n = 617 persons). We demonstrated that bortezomib treatment significantly improved overall response rate (ORR), complete response, a cardiac response rate, 2-year overall survival and the risk of neuropathy and reduced overall mortality compared to controls without bortezomib therapy. From the comparison and subgroup analysis of ORR between bortezomib group and no bortezomib group, the patients with bortezomib had a higher ORR, especially patients pretreated with bortezomib before high-dose melphalan followed by autologous stem cell transplant compared to no pretreatment. In addition, patients with bortezomib in standard dosage had significantly higher ORR. According to our results, bortezomib should be used in AL amyloidosis patients to improve response rate and survival rate and future relevant randomized controlled trials require to be performed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available